DURHAM, N.C.--(BUSINESS WIRE)--BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has announced the acquisition of IPM ...
FDA grants Breakthrough Device Designation to BioAgilytix’s anti-AAV antibody assay supporting Lexeo’s gene therapy for Friedreich ataxia. DURHAM, NC, UNITED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results